No connection

Search Results

HYPR vs SEER

HYPR
Hyperfine, Inc.
NEUTRAL
Price
$1.21
Market Cap
$119.2M
Sector
Healthcare
AI Confidence
85%
SEER
Seer, Inc.
BEARISH
Price
$2.00
Market Cap
$112.8M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
HYPR
--
SEER
--
Forward P/E
HYPR
-3.67
SEER
-1.9
P/B Ratio
HYPR
2.87
SEER
0.43
P/S Ratio
HYPR
8.79
SEER
6.81
EV/EBITDA
HYPR
-2.33
SEER
0.69

Profitability

Gross Margin
HYPR
49.79%
SEER
51.06%
Operating Margin
HYPR
-144.87%
SEER
-413.83%
Profit Margin
HYPR
-262.29%
SEER
0.0%
ROE
HYPR
-79.01%
SEER
-25.08%
ROA
HYPR
-40.61%
SEER
-14.71%

Growth

Revenue Growth
HYPR
128.0%
SEER
5.0%
Earnings Growth
HYPR
--
SEER
--

Financial Health

Debt/Equity
HYPR
0.01
SEER
0.09
Current Ratio
HYPR
4.34
SEER
12.84
Quick Ratio
HYPR
3.56
SEER
12.23

Dividends

Dividend Yield
HYPR
--
SEER
--
Payout Ratio
HYPR
0.0%
SEER
0.0%

AI Verdict

HYPR NEUTRAL

HYPR presents a high-risk, high-reward profile characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation benchmarks due to negative earnings. The company is experiencing explosive revenue growth (128% YoY) and maintains a strong liquidity position with a Current Ratio of 4.34 and negligible debt. However, these strengths are offset by severe profit margins (-262.29%) and a bearish insider sentiment. The stock is currently a speculative growth play where the market is pricing in future scalability rather than current fundamentals.

Strengths
Explosive revenue growth of 128% YoY
Strong liquidity with a Current Ratio of 4.34
Very low leverage (Debt/Equity of 0.01)
Risks
Severe negative profit margins (-262.29%)
Bearish insider activity with consistent selling by C-suite executives
High valuation relative to sales (P/S of 8.79) for a non-profitable firm
SEER BEARISH

SEER exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. Despite a strong current ratio suggesting a remaining cash runway, the company suffers from an abysmal operating margin of -413.83% and stagnant revenue growth of 5%. The long-term price trajectory is catastrophic (-96% over 5 years), and recent insider selling by the CEO and President further signals a lack of confidence in a near-term turnaround.

Strengths
High liquidity with a current ratio of 12.84
Very low debt-to-equity ratio (0.09)
Positive gross margin (51.06%)
Risks
Extreme operational inefficiency (Operating Margin -413.83%)
Critical Piotroski F-Score (1/9) indicating systemic financial weakness
Stagnant revenue growth (5% YoY) for a biotechnology firm

Compare Another Pair

HYPR vs SEER: Head-to-Head Comparison

This page compares Hyperfine, Inc. (HYPR) and Seer, Inc. (SEER) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile